The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)-;which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Researchers found that vaccine effectiveness was 80% and 81% against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

Italy's Recordati expects minimal impact from proposed U.S. pharma tariffs. Canada's Health Canada approves Moderna's RSV ...

A Winnipeg mother with a newborn is pleading with the province to start offering RSV shots to all babies. As we navigate ...